LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Sanofi

Closed

50.48 1.96

Overview

Share price change

24h

Current

Min

49.14

Max

50.55

Key metrics

By Trading Economics

Income

1.4B

1.9B

Sales

3B

11B

P/E

Sector Avg

17.382

51.198

EPS

1.022

Dividend yield

4.5

Profit margin

17.65

Employees

82,878

EBITDA

2.2B

2.8B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+25% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

4.50%

2.40%

Market Stats

By TradingEconomics

Market Cap

-17B

121B

Previous open

48.52

Previous close

50.48

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

Sanofi Chart

Past performance is not a reliable indicator of future results.

Related News

2 Jun 2025, 16:05 UTC

Major Market Movers

Nurix Therapeutics Stock Climbs as Sanofi Extends License for STAT6

2 Jun 2025, 09:17 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 Jun 2025, 05:31 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

22 May 2025, 12:02 UTC

Major Market Movers
Acquisitions, Mergers, Takeovers

Vigil Neuroscience Shares Surge After Sanofi's Planned Acquisition

22 May 2025, 00:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for About $470 Million

2 Jun 2025, 13:50 UTC

Earnings
Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 Jun 2025, 12:33 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi Portfolio Approach Awaits Proof of Improvement -- Market Talk

2 Jun 2025, 10:50 UTC

Acquisitions, Mergers, Takeovers

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 Jun 2025, 10:05 UTC

Market Talk
Acquisitions, Mergers, Takeovers

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 Jun 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 Jun 2025, 05:06 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 Jun 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 Jun 2025, 05:05 UTC

Acquisitions, Mergers, Takeovers

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 Jun 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 Jun 2025, 05:04 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 Jun 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Blueprint Medicines Corporation

2 Jun 2025, 05:02 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Acquire Blueprint Medicines Corporation

30 May 2025, 08:58 UTC

Hot Stocks

Stocks to Watch Friday: Dell, Marvell, Gap, Ulta -- WSJ

30 May 2025, 08:56 UTC

Market Talk

Sanofi, Regeneron Hit by Trial Disappointment -- Market Talk

27 May 2025, 05:03 UTC

Acquisitions, Mergers, Takeovers

Sanofi Closes Acquisition of DR-0201 From Dren Bio

27 May 2025, 05:00 UTC

Acquisitions, Mergers, Takeovers

Press Release: Sanofi Completes Acquisition Of DR-0201 >SAN.FR

21 May 2025, 23:33 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 May 2025, 23:32 UTC

Acquisitions, Mergers, Takeovers

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 May 2025, 23:23 UTC

Acquisitions, Mergers, Takeovers

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 May 2025, 23:22 UTC

Acquisitions, Mergers, Takeovers

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 May 2025, 23:20 UTC

Acquisitions, Mergers, Takeovers

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 May 2025, 23:18 UTC

Acquisitions, Mergers, Takeovers

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

12 May 2025, 12:07 UTC

Market Talk

Trump's Drug Price Cap Plan Is 'Alarming' for Pharma Sector -- Market Talk

8 May 2025, 17:55 UTC

Earnings

Why This Shrinking Covid-19 Vaccine Stock Jumped 30% -- Barrons.com

Peer Comparison

Price change

Sanofi Forecast

Price Target

By TipRanks

25% upside

12 Months Forecast

Average 62.2 USD  25%

High 67 USD

Low 56 USD

Based on 5 Wall Street analysts offering 12 month price targets forSanofi - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

2

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

51.665 / 52.38Support & Resistance

Short Term

Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.